On December 19, MSD announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for V116, its 21-valent pneumococcal conjugate vaccine specifically designed to protect adults.
Merck's 21-Valent Pneumococcal Conjugate Vaccine V116 Receives FDA Priority Review
Dec 19, 2023 23:25
CST Updated
23:25
MSD
Pharmaceutical R&D and Manufacturer
FDA
U.S. Food and Drug Administration